Clinical Professor, Department of Psychiatry
To see if Martin Leamon is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
UC Davis Health Substance Use Disorders Treatment Clinic
2000 Stockton Blvd.
Sacramento, CA 95817
Clinic Phone: 916-734-3574
Substance use disorders are disorders of brain function with emotional, psychological, behavioral, spiritual, physical and social manifestations. Treatment is guided by current clinical research, patient preference and availability of resources. Everyone’s needs are unique and care is a collaborative, ongoing, adaptable endeavor.
Dr. Leamon is an Addictions Psychiatrist who provides office-based outpatient treatment for Substance Use Disorders, including medication-assisted therapy for Opioid Use Disorders with buprenorphine or naltrexone. He works with an integrated team from social work, pharmacy and nursing.
Dr. Leamon's academic interests are in substance use disorders, systems of care and medical education, but since he mainly works collaboratively, they are often swayed by what his friends are interested in convincing him to do.
B.A., Dartmouth College, Hanover NH 1979
M.D., Boston University School of Medicine, Boston MA 1985
Psychiatry, Letterman Army Medical Center, San Francisco CA 1985-1986
Psychiatry, Letterman Army Medical Center, San Francisco CA 1986-1989
“Top Doctor” in Addiction Medicine, Sacramento region. Selected by independent peer survey for Sacramento Magazine 2016, 2017, 2018, 2019, 2020, 2021
Distinguished Lifetime Fellow, American Psychiatric Association, 2020
Fellow, American Society of Addiction Medicine, 2020
Kaiser Hospitals Foundation Award for Teaching Excellence, 2006
Teacher of the Year, Western Region, Association for Academic Psychiatry, 2005
Distinguished Fellow, American Psychiatric Association, 2003
McCarthy JJ, Graas J, Leamon MH, Ward C, Vasti EJ, Fassbender C. The Use of the Methadone/Metabolite Ratio (MMR) to Identify an Individual Metabolic Phenotype and Assess Risks of Poor Response and Adverse Effects: Towards Scientific Methadone Dosing. J Addict Med. 2020 Sep/Oct;14(5):431-436. doi:10.1097/ADM.0000000000000620. PMID:32032212.
Leamon MH, Bakerjian D, Kayingo G, Edwards J, Cachu AM, Yang C. A needs assessment of MAT education among health providers who work with interprofessional learners. Am J Addictions. 2020;29:228-229. Poster abstract.
McCarthy JJ, Vasti EJ, Leamon MH, Graas J, Ward C, Fassbender C. The Use of Serum Methadone/Metabolite Ratios to Monitor Changing Perinatal Pharmacokinetics. J Addict Med. 2018 May/Jun;12(3):241-246. doi:10.1097/ADM.0000000000000398. PMID:29521669.
McCarthy JJ, Leamon MH, Finnegan LP, Fassbender C. Opioid dependence and pregnancy: minimizing stress on the fetal brain. Am J Obstet Gynecol. 2017 Mar;216(3):226-231. doi:10.1016/j.ajog.2016.10.003. Epub 2016 Oct 8. PMID:27729254.
Leamon MH. Prescription Drug Abuse and Mental Illness. Audio-Digest Psychiatry. 2015;44(23).
McCarthy JJ, Leamon MH, Willits NH, Salo R. The effect of methadone dose regimen on neonatal abstinence syndrome. J Addict Med. 2015 Mar-Apr;9(2):105-10. doi:10.1097/ADM.0000000000000099. PMID:25599433.
Salo R, Fassbender C, Iosif AM, Ursu S, Leamon MH, Carter C. Predictors of methamphetamine psychosis: history of ADHD-relevant childhood behaviors and drug exposure. Psychiatry Res. 2013 Dec 15;210(2):529-35. doi:10.1016/j.psychres.2013.06.030. Epub 2013 Jul 26. PMID:23896355.
Leamon MH, Wright T, Myrick H. Substance-Related Disorders. Hales RE, Yudofsky SC, Gabbard GO (eds.). Essentials of Psychiatry, 3rd Edition, American Psychiatric Publishing, Inc, Washington DC. 2011:83-110.
Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011 Apr 30;186(2-3):356-61. doi:10.1016/j.psychres.2010.09.014. Epub 2010 Nov 4. PMID:21055832.
Sokolski EA, Lew ST, Keenan CR, Leamon MH. Substance-Use Disorders – Alcohol. McCarron RM et al (eds.). Primary Care Psychiatry, 2nd Edition, Philadelphia, Wolters Kluwer. 2019:175-192.